医疗器械互联网信息服务

Search documents
1.19亿元!辰光医疗最新年报
思宇MedTech· 2025-05-07 09:03
Core Viewpoint - The article discusses the financial performance of Chenguang Medical in 2024, highlighting significant declines in revenue and net profit compared to previous years, indicating potential challenges for the company moving forward [2][3]. Financial Performance - In 2024, the company achieved operating revenue of 119 million, a decrease of 28.16% compared to 2023 [2][3]. - The net profit attributable to shareholders was -60.89 million, reflecting a decline of 416.85% year-on-year [2][3]. - The net profit after deducting non-recurring gains and losses was -68.39 million, down 268.45% from the previous year [2][3]. - The gross profit margin improved to 38.24% from 35.01% in the previous year [2]. - The basic earnings per share were -0.71, a significant drop of 407.14% compared to -0.14 in 2023 [2]. Cash Flow and Expenses - The net cash flow from operating activities was -28.48 million, a decrease of 82.06% year-on-year [8]. - Total expenses for the year were 90.94 million, an increase of 2.11 million compared to the previous year, with an expense ratio of 76.42%, up 34.25 percentage points [8]. Business Overview - Chenguang Medical focuses on the research, development, production, and sales of MRI systems and their core components, including superconducting magnets and RF detectors [6][7]. - The company aims to drive business growth through technological innovation and market expansion, optimizing its product line and enhancing market competitiveness [9]. - In 2024, the company expanded its operations to include internet information services for medical devices and various medical device production and management [9].